Sermorelin

Sermorelin is identified as the 1-29 fragment of human growth hormone-releasing hormone. The source reports that it engages GHRH receptors in the anterior pituitary, prompting endogenous growth hormone production and pulsatile release while remaining within normal somatostatin-mediated feedback control.

The source describes Sermorelin as having historical clinical use rather than only informal peptide-market interest. It reports FDA approval in 1990 for diagnosing GH deficiency and a 1997 approval for pediatric idiopathic GH deficiency with growth failure, with studies described as showing increased GH release and growth velocity after about six months of daily injections. It also cites work in which intravenous Sermorelin was used as a relatively specific GH-deficiency test with few false positives, and once-daily subcutaneous use supported growth in some GH-deficient prepubertal children. For adult anti-aging use, the source characterizes the evidence as much thinner, noting a 2006 editorial that favored Sermorelin conceptually over recombinant GH for age-related GH decline while acknowledging limited long-term clinical data. Commercial discontinuation in 2008 is attributed to business reasons rather than safety in the source, leaving current adult use tied to compounded, off-label contexts and limited modern trial evidence.